EU launches two new 15 Mio € projects building on IHEC data to foster innovative and precise treatment of inflammatory disordersJanuary 18, 2017
With the aim to foster novel innovative and precise treatment of inflammatory disorders, the European Commission has awarded two new personalised medicine projects 15 million euros each. The two projects extend the EU´s engagement in large reference research initiatives in the field of medical life sciences: Succeeding the successful completion of BLUEPRINT, the previous EU flagship project associated to IHEC ending last September, both projects will significantly build on epigenetic data generated within IHEC to successfully implement a personalised approach to immune system disorders and beyond.
Chronic inflammatory diseases and autoimmunity constitute a group of incurable disorders of the immune system with a lifetime prevalence of over 10% in Europe. The diseases have a broad impact on the quality of life of individual patients and their families and pose a global burden to healthcare systems due to rising therapy costs and disease-related disability. The diseases are characterised by a lack of molecular biomarkers for early, unambiguous diagnosis as well as by a lack of strategies for predicting disease outcome and/or response to different therapies.
In response to these needs, the two new consortia MultipleMS and SYSCID join together top-level European and EU-associated research teams to set new standards in personalised and precise diagnostic and therapeutic approaches for this debilitating group of disorders.
The MultipleMS consortium coordinated by Karolinska Institutet (KI) in Sweden focuses on novel and better treatments for multiple sclerosis (MS). In this project, universities and companies across 12 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
The SYSCID project is coordinated by Kiel University in Germany and focuses on multidimensional biomarker interpretation from blood and stool for a personalised approach to inflammatory bowel disease, rheumatoid arthritis and systemic lupus erythematosus. Academic and industry partners from 9 different countries join forces to achieve these ambitious goals.
With an improved prediction of disease outcome and potential response to treatment, both projects will contribute to an improvement of medical care in the diseases under study reducing the time to optimal treatment and individual disease burden. Moreover, the approaches will serve as a blueprint for future development of precision medicine in other fields.